For research use only
| Cat No. | ABC-TC0129 |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | T cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Product Code | CCRF-CEM C3; CEM-C3; CEM/C3; CEMC3 |
Discover the CEM-CM3 cell line, a vital tool for cancer research, offering insights into therapeutic responses and cellular mechanisms in oncology studies.
CEM‑CM3 is a human T‑lymphoblastoid cell line derived in situ from the peripheral blood of a 4‑year‑old with childhood T‑cell acute lymphoblastic leukemia (T‑ALL), selected from the parental CCRF‑CEM cell line for 8‑azaguanine resistance. The cells grow in suspension, exhibiting lymphoblast morphology. Cytogenetically, they retain a diploid modal chromosome number and carry mutations in FBXW7 (p.R465C), FLT3 (p.A627T), KRAS (p.G12D), NOTCH1 (insertions and point mutations), and TP53 (p.R175H, p.R248Q). STR profiling confirms authenticity. Used historically as fusion partners in hybridoma production, the line is non‑tumorigenic in nude mice. Gene expression mirrors T‑cell lineage with active TCR signaling. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | CCRF-CEM C3; CEM-C3; CEM/C3; CEMC3 |
| Species | Human |
| Cat.No | ABC-TC0129 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | T cell |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
CEM‑CM3 serves as a versatile T‑ALL research model, especially well-suited for studies on chemoresistance due to its 8‑azaguanine resistance phenotype. It is widely used to examine oncogenic signaling pathways involving KRAS, NOTCH1, FLT3, and TP53 mutations. Its historical role as a hybridoma fusion partner makes it useful in antibody production and immunotherapy assay development. The cell line supports drug screening, cytotoxicity testing, and functional genomics, including studies of apoptosis and DNA damage response influenced by its TP53 status.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
